Asset
Risperidone
Indivior Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01677377 | phase2 | completed | 2012-08-01 | 2013-04-01 | Indivior Inc. | Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy |
| NCT02109562 | phase3 | completed | 2014-04-01 | 2014-11-01 | Indivior Inc. | Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients |
| NCT03978832 | phase4 | completed | 2019-06-28 | 2020-05-12 | Indivior Inc. | Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone |
| NCT02768649 | phase1 | completed | 2011-04-01 | 2012-02-01 | Indivior Inc. | Single Ascending Dose Study of RBP-7000 |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 210655 | NDA | INDIVIOR INC |
Marketed products (2)
- PERSERIS KIT
- PERSERIS KIT